Proportion of CD94/NKG2A-expressing cells in paired PreG- and G-PBMC before and after stimulation by anti-CD3 monoclonal antibody
. | Before . | . | After anti-CD3 stimulation . | . | Anti-CD3 and IL-15 . | . | |||
|---|---|---|---|---|---|---|---|---|---|
| Surface marker . | PreG . | G-PBMC . | PreG . | G-PBMC . | PreG . | G-PBMC . | |||
| CD94+/CD3+ | 5.7 ± 3.1 | 4.6 ± 1.9 | 8.4 ± 4.4 | 17.2 ± 8.7* | 24.2 ± 10.4 | 32.8 ± 8.2† | |||
| CD94+/CD8+ | 2.6 ± 1.6 | 2.7 ± 1.2 | 7.3 ± 4.0 | 15.2 ± 8.4* | 17.6 ± 10.0 | 24.2 ± 5.6‡ | |||
| NKG2A+/CD3+ | 1.8 ± 1.4 | 1.8 ± 0.7 | 3.0 ± 1.9 | 6.3 ± 5.0 | 11.3 ± 7.1 | 16.9 ± 7.7‡ | |||
| NKG2A+/CD8+ | 0.5 ± 0.3 | 0.4 ± 0.5 | 2.3 ± 1.3 | 5.1 ± 4.3 | 8.6 ± 3.1 | 13.6 ± 6.3* | |||
. | Before . | . | After anti-CD3 stimulation . | . | Anti-CD3 and IL-15 . | . | |||
|---|---|---|---|---|---|---|---|---|---|
| Surface marker . | PreG . | G-PBMC . | PreG . | G-PBMC . | PreG . | G-PBMC . | |||
| CD94+/CD3+ | 5.7 ± 3.1 | 4.6 ± 1.9 | 8.4 ± 4.4 | 17.2 ± 8.7* | 24.2 ± 10.4 | 32.8 ± 8.2† | |||
| CD94+/CD8+ | 2.6 ± 1.6 | 2.7 ± 1.2 | 7.3 ± 4.0 | 15.2 ± 8.4* | 17.6 ± 10.0 | 24.2 ± 5.6‡ | |||
| NKG2A+/CD3+ | 1.8 ± 1.4 | 1.8 ± 0.7 | 3.0 ± 1.9 | 6.3 ± 5.0 | 11.3 ± 7.1 | 16.9 ± 7.7‡ | |||
| NKG2A+/CD8+ | 0.5 ± 0.3 | 0.4 ± 0.5 | 2.3 ± 1.3 | 5.1 ± 4.3 | 8.6 ± 3.1 | 13.6 ± 6.3* | |||
Values indicate the percentage of CD94 or NKG2A-expressing cells (means ± SDs, n = 7). Significant difference were noted when comparing the value of PreG and G-PBMC after stimulation with and without IL-15 (*P < .01; ‡P < .05, †P < .1).